MERIT-2 : Long Term, Multicenter, Single-arm, Open-label Extension Study of the MERIT-1 Study, to Assess the Safety, Tolerabilty and Efficacy of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Latest Information Update: 13 Apr 2023
At a glance
- Drugs Macitentan (Primary)
- Indications Pulmonary hypertension
- Focus Adverse reactions
- Acronyms MERIT-2
- Sponsors Actelion Pharmaceuticals
- 26 Apr 2022 Status changed from active, no longer recruiting to completed.
- 26 Apr 2022 This trial has been completed in the Netherlands (Global end date: 21 Mar 2022).
- 21 Mar 2022 This trial has been completed in Hungary , according to European Clinical Trials Database record.